Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Brexu-Cel Displays Comparable Efficacy Across Age Groups in Relapsed/Refractory B-ALL

December 8th 2024

Brexucabtagene autoleucel demonstrated similar efficacy across age groups of patients with relapsed/refractory B-cell acute lymphoblastic leukemia

Asciminib Continues to Best SOC TKIs as Secondary End Points of ASC4FIRST Trial are Met

December 8th 2024

Treatment with asciminib results in superior efficacy and safety vs investigator-selected TKIs in CML according to updated 96-week data from ASC4FIRST.

Olverembatinib May Be Effective in Second Line for CP-CML

December 8th 2024

Olverembatinib showed potential in patients with chronic-phase chronic myeloid leukemia with prior exposure to first-line second-generation TKIs.

US Real-World Analysis Supports Clinical Benefit of Tafasitamab in R/R DLBCL

December 8th 2024

Data from a retrospective analysis showcase the real-world effectiveness of tafasitamab for relapsed/refractory DLBCL in the United States.

FS118 Showcases Modest Efficacy in Relapsed/Refractory DLBCL

December 8th 2024

FS118, an investigational LAG-3/PD-L1 bispecific antibody, demonstrated an encouraging objective response rate in the relapsed/refractory DLBCL setting.

Oral Revumenib-Based Combo Produces Responses in R/R AML

December 8th 2024

Revumenib plus decitabine/cedazuridine and venetoclax produced responses in relapsed/refractory acute myeloid leukemia.

Revumenib Displays Activity in Relapsed/Refractory KMT2A+ Acute Leukemias

December 8th 2024

Revumenib demonstrated meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia.

Recapping the Latest in AML With Dr Eunice Wang

December 8th 2024

Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, sits down with Chandler Park, MD, FACP, to discuss the latest in acute myeloid leukemia from the 2024 ASH Annual Meeting.

Blinatumomab Plus Chemo Increases DFS Rates in Standard-Risk Pediatric B-ALL

December 7th 2024

Blinatumomab plus chemotherapy significantly improved 3-year DFS rates vs chemotherapy alone in pediatric patients with standard-risk pediatric B-ALL.

Bicistronic CD19/CD22-Directed CAR T-Cell Therapy Is Safe, Elicits Durable Responses in Pediatric R/R B-ALL

December 7th 2024

Treatment with bicistronic CD19/CD22 CAR T-cell therapy led to high 1-year EFS and OS rates among children with relapsed/refractory B-ALL.

Drs Baljevic and Cortes Preview Upcoming Studies and Emerging Data From ASH 2024

December 6th 2024

Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.

TERN-701 Decreases BCR-ABL Levels, Generates Molecular Responses in R/R CML

December 4th 2024

TERN-701 reduced BCR-ABL levels and produced molecular responses in relapsed/refractory chronic myeloid leukemia.

FDA Awards Fast Track Designation to LBS-007 for Acute Myeloid Leukemia

December 3rd 2024

LBS-007 receives fast track status from the FDA for use in patients with acute myeloid leukemia.

OncLive’s November Roundup of Key FDA Approvals in Oncology

December 3rd 2024

Here is your snapshot of all treatment options that the FDA cleared in November 2024 spanning tumor types.

Revisit Every OncLive On Air Episode From November 2024

December 2nd 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

Vice Chair of the B-Cell Lymphomas NCCN Guidelines Maps Critical Changes From 2024

December 2nd 2024

Leo I. Gordon, MD, parses major changes to the 2024 NCCN guidelines for the treatment of patients with MCL, MZL, and follicular lymphoma.

The Addition of Asciminib and Removal of Omacetaxine Mark Notable CML NCCN Guideline Updates

December 1st 2024

Neil P. Shah, MD, PhD, highlights key recent changes to the CML NCCN guidelines and details anticipated data for 2025.

The OncFive: Top Oncology Articles for the Week of 11/24

November 30th 2024

Belantamab mafodotin is under FDA review in multiple myeloma, and Suneel Kamath, MD, highlights pancreatic cancer awareness month.

Obe-Cel Approval Expands CAR T-Cell Therapy Options in Relapsed/Refractory ALL

November 29th 2024

Hematologic oncologists offer their perspective on the current and potential future standing of CAR T-cell therapies in the relapsed/refractory ALL treatment landscape.

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

November 28th 2024

Dr Shaughnessy discusses the significance of the FDA approval of obe-cel for patients with relapsed or refractory B-cell precursor ALL.